SYRE — Spyre Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636282 ·
Last close
$73.65
Market Cap
$6.40B
52W High
$78.80
52W Low
$38.36
ADV30
1,267,031
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -75,641,000 | -69,005,000 | 763,953,000 | 97,185,000 | 93,142,000 |
| Dec 2025 | 0 | — | -57,172,000 | -62,530,000 | 777,781,000 | 85,721,000 | 62,545,000 |
| Sep 2025 | 0 | — | -56,888,000 | -11,183,000 | 504,604,000 | 64,897,000 | 49,504,000 |
| Jun 2025 | 0 | — | -51,935,000 | -36,717,000 | 538,832,000 | 81,659,000 | 83,059,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-169,252,000
Investing CF
$-143,475,000
Financing CF
$309,025,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.09
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,127,635,000
Inventory
—
Receivables
—
ST Investments
$670,812,000
EBIT TTM
$-219,562,000
Pretax Income TTM
$-155,218,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -219,562,000 | -155,203,000 | 777,781,000 | 62,545,000 | — | -169,252,000 |
| Dec 2024 | 0 | -208,566,000 | -208,018,000 | 608,484,000 | 90,680,000 | — | -157,410,000 |
| Dec 2023 | 886,000 | -128,564,000 | -338,790,000 | 341,859,000 | 157,843,000 | — | -99,910,000 |
| Dec 2022 | 2,329,000 | -84,781,000 | -83,815,000 | 71,144,000 | 20,839,000 | — | -80,144,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$174,000
NetIncome TTM
$-127,369,000
OpCashFlow TTM
$0
Assets (Latest)
$608,484,000
Forward EPS
$-3.01
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $70.00 · spot: $73.65 · call volume: 91 · put volume: 77
Expected Move to 2026-06-18:
±$9.95
(13.51%) —
implied range
$63.70 –
$83.60
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | $6.43B | $99.98 | — |
| CORT | CORCEPT THERAPEUTICS INC | $6.48B | $60.36 | — |
| ALKS | Alkermes plc. | $6.23B | $37.35 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
News headlines (Yahoo Finance, 1h cache)
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
2026-05-17 19:13 · Yahoo
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
2026-05-17 19:01 · Yahoo
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
2026-05-17 18:52 · Yahoo
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
2026-05-17 18:42 · Yahoo
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
2026-05-05 17:05 · Yahoo
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-05 12:00 · Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
2026-05-01 20:28 · Yahoo
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise
2026-05-01 19:09 · Yahoo
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
2026-04-30 13:57 · Yahoo
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers
2026-04-27 21:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.